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Abstract
Background: There is limited high-quality research investigating the efficacy of palliative radiation (PPR) with
regard to symptoms and quality of life (QOL) among cancer patients with pelvic soft tissue tumors. As a result,
clinicians are left with mainly retrospective studies, without reliable data on which to base treatment decisions. As
a first step of a subsequent analysis of PPR’s efficacy, we aimed to determine whether it is feasible to prospectively
measure symptoms and QOL among patients treated with PPR. A secondary aim was to explore patients’
willingness to answer existential questions in the setting of palliative pelvic radiation.
Methods: Patients referred for palliative radiation of soft-tissue pelvic tumors were invited to enter the study.
Symptoms were scored by study physicians and QOL was assessed by the EORTC QLQ C-30 questionnaire and site
specific modules (PR25, CR38 or BL24) prior to start of radiation and 6 and 12 weeks after its completion. In
addition, patients answered existential questions at each of the study visits. A radiation therapist was available to
participants in order to answer their questions and ensure that questionnaires were completed.
Findings: Five female and 17 male patients with prostate cancer (14), colorectal cancer (5) and bladder cancer (3)
were included in the study. The median age of the participants was 75 years (range 62-90). Twenty patients were
still in the study at the 6-week follow-up and 18 patients at the 12-week follow-up. Twenty-one patients had valid
responses within all the EORTC QLQ C-30 scales at baseline, 20/20 at the 6-week follow-up and at the 12-week
follow-up 17/18 patients still in the study had valid responses within all scales. This level of response was similar in
the site-specific modules and among the existential questions.
Discussion: Among patients with prostate, colorectal and bladder cancer, compliance to questionnaires assessing
symptoms, QOL and existential questions 6 and 12 weeks after PPR is sufficient to enable evaluation in a larger
and more homogeneous patient group in order to reach clinically valid conclusions as to the efficacy of PPR.
Background
The incidences of prostate, colorectal and bladder cancers
continue to rise in many western societies [1] as well as in
many developing countries as they adopt a more “western”
lifestyle [2]. Steadily increasing life-expectancy contributes
to increased incidence [3] and with advancements in sys-
temic treatments such as hormonal manipulation, biologi-
cal agents and chemotherapy, patients can potentially live
for many months and even years with advanced stages of
malignancy. Palliative pelvic radiation (PPR) is a treatment
option with a long clinical tradition in cases of sympto-
matic pelvic tumors [4-6].
In PPR, there exists a fine balance between ameliorat-
ing cancer symptoms versus the potential drawbacks of
treatment toxicity and complications, as well as valuable
time spent ("lost”) in treatment. Radiation oncologists
use PPR to treat pain, bleeding, and obstruction, in an
effort to indirectly enhance patients’ quality of life (QOL)
[7]. Physician assessment of symptoms and patient well-
being often falls short [8] and ultimately, it is the patients’
subjective experience of symptom burden, treatment-
related side effects and quality of life that are the impor-
tant and clinically valid endpoints in palliation. There is,
however, limited evidence-based information to support
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the efficacy of PPR with regard to symptoms and QOL of
patients with bladder cancer [9,10] and even less so in
cases of prostate [11], and colorectal [12] cancers.
Potential areas of practical and ethical conflict in the
investigation of palliative treatments include: (a) defining
the patient group, (b) inclusion and follow-up of termin-
ally ill patients in a research protocol, and (c) addressing
the effects of confounding treatments [13]. Conse-
quently, palliative treatment regimens are often based
on local tradition and clinical anecdotes, without hard
scientific evidence.
To the best of our knowledge, there exist no published
prospective evaluations of PPR among patients with pros-
tate, and colorectal cancer, and only one randomized trial
among patients with bladder cancer, that adequately
describe its effects on symptoms and QOL. In order to
clarify the indication for and dosage of this common pro-
cedure, reliable documentation of its effects is necessary.
Due to the challenges inherent to this type of research, a
pilot study was regarded as a natural first step in this pro-
cess. The purpose of this study was to determine whether
it is feasible to prospectively measure symptoms and QOL
among patients treated with PPR. A secondary aim was to
explore patients’ willingness to answer existential ques-
tions in the setting of palliative pelvic radiation.
Methods
Patients
All patients referred to the Center for Cancer Treatment,
Sørlandet Hospital Trust, Kristiansand for fractionated
palliative radiation of soft-tissue pelvic tumors were
screened for eligibility. Eligibility criteria were as follows:
age ≥ 18 years, histologically or cytologically proven color-
ectal (CRC), bladder (BC), or prostate cancer (PC),
planned palliative fractionated radiotherapy of soft tissues
(not skeletal metastases), life expectancy > 3 months, abil-
ity to understand spoken and written Norwegian, no sig-
nificant cognitive impairment, no treatment with
investigational therapy and signed informed consent.
In our institution, fractionated pelvic radiotherapy is
given to patients with Eastern Cooperative Oncology
Group (ECOG) functional status [14] two or better.
ECOG functional status three or worse was therefore an
indirect exclusion criterion. Due to the exploratory nature
of the feasibility study, concomitant treatment with other
anti-tumor therapies (chemotherapy, hormonal manipula-
tion, etc.) was not an exclusion criterion.
Radiation treatment
Fractionation schemes were determined by the treating
radiation oncologist prior to referral to the study. Two to
four radiation fields with six or 15 megavoltage photon
beam radiation were used. Treatment fields were planned
based on computed tomography of the pelvis and the
target volumes consisted of gross tumor with 1-2 cm
margins.
Measurements/evaluation
There were three study visits. The baseline evaluation took
place just prior to radiation, and follow-ups were done six
and twelve-weeks after completion of radiotherapy. At
each visit, the study physician completed a prospective
evaluation of symptoms, functional status, medications
and complications. Participants completed questionnaires
while in the treatment center, assisted by a radiation thera-
pist when necessary. Blood tests, consisting of hematology,
liver and renal function, electrolytes, and tumor markers
were taken as pre-radiation routine.
QOL was assessed by the European Organization for
the Research and Treatment of Cancer Quality of Life
Questionnaire C-30 (EORTC QLQ C-30, v.3.0) core
questionnaire, developed and validated for use among
cancer patients world-wide [15]. It covers aspects of
QOL considered to be relevant to most cancer patients,
and includes five functional scales (physical, role, emo-
tional, cognitive and social), three symptom scales (fati-
gue, pain and nausea and vomiting), a global QOL scale
as well as five symptoms common among cancer patients
(dyspnoea, anorexia, insomnia, constipation and diarrhea)
and perceived financial impact of the disease and treat-
ment. This questionnaire has been validated for use
among Norwegian patients with heterogeneous cancer
diagnoses [16] and among those receiving palliative
radiation [17]. In addition, patients filled out site specific
modules, depending on their diagnosis (PR25 = Prostate
cancer module [18], CR38 = Colorectal cancer module
[19] or BL24 = Bladder cancer module), in order to cover
additional aspects of QOL considered relevant to these
specific cancer types.
At each of the three study visits, patients also answered a
seven-item module of questions regarding existential
issues and life outlook, extracted from the 81-item Impact
of Cancer (IOC) Instrument [20]. These questions can be
found in Table five.
Analysis
Descriptive statistics were used to summarize patient
accrual, survey completion, survival and withdrawals
from the study.
Ethics
Participants were given written and oral information
about their planned palliative radiation treatment and
about the pilot study by an oncologist. All participants
signed an informed consent form. Approval for the
study was granted by the Regional Ethics Committee,
the Norwegian Social Science Data Services and the
Hospital Research Board.
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Findings
The study screened 26 and enrolled 22 patients between
March 2008 and April 2009 (table 1). Reasons for non-
enrollment were patient choice (belief that the study
procedure and questionnaires were too demanding) in
three cases and cancellation of planned radiotherapy
due to clinical deterioration and progressive disease in
one case.
Eight patients were still alive 18 months after the pilot
study was closed. All but one patient survived for the
duration of the study (duration of radiation treatment
plus 12 weeks follow-up). Three patients did not com-
plete the study due to clinical deterioration and one
patient moved away from the region prior to the 6 week
follow-up.
Radiotherapists assisted patients as-needed and
encouraged them to complete the questionnaires inde-
pendently. The amount of time used per patient ranged
from zero to 30 minutes. The primary reasons for radio-
therapist assistance were difficulty reading questions and
difficulty with written responses. In addition, there were
occasional issues of question clarification and reminders
to fill out the forms in their entirety (table 2).
Questions regarding sexuality were answered by 20
patients (91%) at baseline, 18 (82%) at the 6-week fol-
low-up and 13 (59%) at the 12-week follow-up. These
were the most frequent single-item omissions.
Pre-treatment responses to EORTC QLQ-C30 (table
3) and existential questions (table 4) are reported in
order to give an indication of the baseline symptom bur-
den and general health of our cohort.
21/22 patients answered the IOC questions about exis-
tential matters at baseline. At the six week follow-up 19
patients answered the existential questions fully and at
the 12-week follow-up 16 patients answered the existen-
tial questions fully.
Discussion
The findings of the present pilot study show that it is
feasible, within a research project, to prospectively eval-
uate symptoms, QOL and existential issues among
patients undergoing PPR for locally advanced prostate,
colorectal and bladder cancers.
Patient accrual in this pilot study was good, with 85%
of potential candidates included, despite a rather
demanding protocol, with over two hundred question-
naire items per participant.
Study withdrawal was the largest contributor to the
decline in response rates between baseline and the six
and 12-week follow-ups. Reasons for study withdrawal
depended on patients’ declining general health. This is to
be expected in a population with such advanced malig-
nancy and relatively limited life-expectancy [22].
For the patients that remained in the study for its dura-
tion, however, completion of questionnaires did not
appear to be too rigorous and as seen in previous reports,
it was the questions related to sexuality that were most
commonly omitted by patients filling out the EORTC
questionnaires [23]. In our small cohort, patients who
were physically able to come to the follow-up appoint-
ments all filled out the required questionnaires sufficiently
and reported that they enjoyed participating, despite the
fact that the questionnaire procedure required roughly
thirty minutes of additional time spent at each of the three
study visits. The fact that the radiation therapist ensured
that the forms were complete prior to patients leaving the
treatment center is likely to have improved questionnaire
response rates [24].
This feasibility study used clinically acceptable meth-
ods, while exploring the question of QOL using validated
research tools (BL24 was the only module not finally vali-
dated). An overly ambitious protocol can hamper accrual,
questionnaire response rates, and study completion, par-
ticularly in a palliative population. The EORTC QLQ
Table 1 Characteristics of included patients (N = 22)
Age, years
Median 75
Range 62-90
Sex
Male 17
Female 5
Diagnosis
Prostate cancer 14
Colorectal cancer 5
Bladder cancer 3
Baseline ECOG performance status
0 3
1 14
2 5
Radiation schedules
2 Gy × 25 = 50 Gy 7(6 PC, 1 CRC, 1 BC*)
3 Gy × 10 = 30 Gy 6(3 PC, 2 CRC, 1 BC)
2 Gy × 30 = 60 Gy 4(4 PC)
3 Gy × 13 = 39 Gy 2(1 CRC, 1 BC)
2 Gy × 20 = 40 Gy 1(1 PC)
4 Gy × 5 = 20 Gy 1(1 CRC)
Survival (in months) from last radiation
treatment
3 month survival 91%
6 month survival 73%
1 year survival 68%
2 year survival 36%
*One patient with bladder cancer did not complete the planned radiotherapy
regimen (completed 13 fractions of the planned 2Gy × 25) due to general
fatigue and a wish to be discharged from the hospital. The remaining 21
patients completed their prescribed treatments.
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Table 2 EORTC QLQ completion rates
Study
contact
Number of completed C30 and site-specific
questionnaires/eligible patients
Diagnoses of patients who filled out the
questionnaires/eligible patients
Overall
response rates
Baseline 21/22 14/14 PC
4/5 CRC
3/3 BC
95%
6 week
follow-up
20/22 13/14 PC
5/5 CRC
2/3 BC
91%
12 week
follow-up
17/22 11/14 PC
4/5 CRC
2/3 BC
77%
Table 3 Baseline responses to EORTC QLQ-C30
Not at all
(n)
A little
(n)
Quite a bit
(n)
Very much
(n)
1. Do you have any trouble doing strenuous activities like carrying a heavy shopping bag
or a suitcase?
6 8 5 2
2. Do you have any trouble taking a long walk? 7 4 5 5
3. Do you have any trouble taking a short walk? 14 3 2 2
4. Do you need to stay in bed or a chair during the day? 5 6 7 3
5. Do you need help with eating, dressing, washing yourself or using the toilet? 21 0 0 0
During the past week:
6. Were you limited in doing either your work or other daily activities? 4 9 4 4
7. Were you limited in pursuing your hobbies or other leisure time activities? 5 6 4 5
8. Were you short of breath? 14 1 6 0
9. Have you had pain? 6 5 8 2
10. Did you need to rest? 1 9 8 3
11. Have you had trouble sleeping? 11 5 3 2
12. Have you felt weak? 5 8 5 3
13. Have you lacked appetite? 10 6 3 2
14. Have you felt nauseated? 15 4 2 0
15. Have you vomited? 17 3 0 0
16. Have you been constipated? 8 8 2 3
17. Have you had diarrhea? 14 4 2 1
18. Were you tired? 3 9 6 3
19. Did pain interfere with your daily activities? 7 5 5 4
20. Have you had difficulty in concentrating on things, like reading a newspaper or
watching television?
18 2 1 0
21. Did you feel tense? 14 5 1 1
22. Did you worry? 11 8 1 1
23. Did you feel irritable? 13 5 3 0
24. Did you feel depressed? 11 7 2 0
25. Have you had difficulty remembering things? 13 5 3 0
26. Has your physical condition or medical treatment interfered with your family life? 10 4 6 1
27. Has your physical condition or medical treatment interfered with your social activities? 6 7 6 2
28. Has your physical condition or medical treatment caused you financial difficulties? 20 1 0 0
Very
poor
Excellent
1 2 3 4 5 6 7
29. How would you rate your overall health during the past week? (n) 0 1 7 5 2 4 2
30. How would you rate your overall quality of life during the past
week? (n)
0 1 4 5 4 5 2
As answered at baseline by 21 of the 22 included patients. There were three single-item omissions (questions 7, 15 and 24) among these 21 responders.
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questionnaires were chosen because of their comprehen-
siveness, ease of use, and the high levels of reliability and
validity they have demonstrated in two decades of inter-
national research [25]. We chose the EORTC QLQ-C30
and its corresponding diagnosis-specific modules rather
than the EORTC palliative module (QLQ-C15-PAL)
because of the more comprehensive symptom data that
could be gathered using the diagnosis-specific modules.
The use of selected existential questions taken from
the IOC instrument is a limitation of this pilot study.
Psychometric tests of these items were not carried out
on our small cohort and as far as we know, these ques-
tions have not been tested for validity or reliability
among patients with advanced cancer. The complete
IOC questionnaire, which is a larger and more complex
instrument, has been psychometrically tested among
long-term cancer survivors [27]. Fundamental differ-
ences between the context of palliative treatment and
the context of long-term cancer survivorship are likely
to impact on the responses to existential questions,
thereby limiting our ability to interpret these findings.
This pilot study did not seek to evaluate the effects of
the PPR but to test the feasibility of such an evaluation.
With a hypothetical primary endpoint of QOL at 12
weeks post-radiation, 17 patients (77%) would have been
evaluable in this study (table 2). At 6 weeks, this num-
ber was 90%. Considering the obstacles inherent to
research among palliative patients, these are encouraging
results. This study also demonstrates that patients
receiving palliative radiation are willing and able to
answer selected existential questions regarding their ill-
ness and outlook on life.
The survival statistics in table 2 as well as the baseline
questionnaire responses with regard to symptom burden
and QOL (table 3) demonstrate that many of the
patients in this small cohort were in relatively good
health, considering their diagnoses of incurable cancer.
Although this was not an inclusion criterion, it does
potentially limit the generalizability of this pilot study.
Our study included all-comers scheduled to receive
fractionated PPR. Treatments were prescribed based on
patients’ general health and estimated life-expectancies.
The group of ten prostate cancer patients who received
50-60 Gy (five or six weeks of treatment) was a sub-
group of patients with relatively long life-expectancies
(often over a year). In contrast, some of our patients
had life expectancies of little more than 12 weeks and
were chosen for shorter treatment courses (20-30 Gy),
for precisely that reason. Such inhomogeneity of the
patient cohort, with respect to life expectancies, may
represent a problem in a scientific study, but is a com-
mon experience in the palliative cancer care practice.
There is no clear consensus for the optimal dose or
schedule of PPR in prostate, rectal and bladder cancers.
Preferred radiation dose and method of delivery often
depend not only on target symptom and tumor type,
but also on a range of non-clinical factors such as dis-
tance to treatment center. Just among the 22 patients
studied here, six different fractionation schedules were
used, varying in faction sizes from two to four Gy and
total doses of 20-60 Gy. These treatment approaches
entail significantly different burdens on the patients. A
more homogeneous population and fractionation sche-
dule would therefore be needed in order to reach con-
clusions about the effects and side-effects of the studied
treatment.
Conclusions
This evaluation of symptoms, QOL and existential ques-
tions among PPR patients at 6 and 12 weeks after treat-
ment yields encouraging response rates. The greatest
challenge is patient withdrawal because of clinical
Table 4 Seven Existential questions taken from the IOC Instrument
Completely agree (n) Agree (n) Neutral (n) Disagree (n) Completely disagree (n)
Positive Outlook
Having had cancer has made me realize
that time is precious.
8 7 4 0 2
Having had cancer has strengthened my
religious faith or my sense of spirituality.
9 0 8 2 2
I learned something about life because of
having had cancer.
3 10 6 0 2
Negative Outlook
Having had cancer makes me feel unsure
about my future.
6 5 6 1 3
I worry about my future. 3 5 4 3 6
I am afraid to die. 1 3 4 6 7
I feel like time in my life is running out. 3 5 2 9 2
As answered at baseline by 21 of the 22 included patients. There were no single item omissions.
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deterioration. While it is inherent in the population we
are studying, this problem is beyond the scope of the
protocol and must therefore be taken into consideration
in further protocol development. The availability of a
radiation therapist to assist patients during data collec-
tion appears to have contributed to response rates. The
procedure used among these 21 heterogeneous study
patients has shown feasibility and is therefore being
implemented in a larger Norwegian multicenter study
with a more uniform treatment regimen and sample of
prostate and rectal cancer patients, in order to reach
clinically significant conclusions about the effects of
PPR [28].
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